Alexander Azoy, chief accounting officer of Arcus Biosciences Inc. (NASDAQ: RCUS), sold 2,827 common shares on August 21 at $30.00 each, totaling $84,810, under a Rule 10b5-1 trading plan initiated in January 2024.
The transaction followed the exercise of 2,827 stock options at an exercise price of $15.44 per share, costing $43,648. Azoy retains direct ownership of 39,581 shares, including unvested restricted stock units, and holds 3,073 exercisable options vesting in 48 equal monthly installments through January 2024.
Arcus Biosciences' stock has gained 186% over the past year and was trading near its 52-week high of $31.73 at the time of the sale. The company reported adjusted EPS of -$0.72 for Q2 2026, beating the -$0.90 estimate, and revenue of $41 million, nearly double the $22.22 million forecast. Cash reserves are projected to extend through at least the second half of 2028.
InvestingPro noted the stock as slightly overvalued relative to its fair-value estimate, with four analysts raising earnings projections for the upcoming period.
